| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC39A5 |
| Uniprot No | Q6ZMH5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-539 aa |
| 活性数据 | VGGSVPNLGPAEQEQNHYLAQLFGLYGENGTLTAGGLARLLHSLGLGRVQGLRLGQHGPLTGRAASPAADNSTHRPQNPELSVDVWAGMPLGPSGWGDLEESKAPHLPRGPAPSGLDLLHRLLLLDHSLADHLNEDCLNGSQLLVNFGLSPAAPLTPRQFALLCPALLYQIDSRVCIGAPAPAPPGDLLSALLQSALAVLLLSLPSPLSLLLLRLLGPRLLRPLLGFLGALAVGTLCGDALLHLLPHAQEGRHAGPGGLPEKDLGPGLSVLGGLFLLFVLENMLGLLRHRGLRPRCCRRKRRNLETRNLDPENGSGMALQPLQAAPEPGAQGQREKNSQHPPALAPPGHQGHSHGHQGGTDITWMVLLGDGLHNLTDGLAIGAAFSDGFSSGLSTTLAVFCHELPHELGDFAMLLQSGLSFRRLLLLSLVSGALGLGGAVLGVGLSLGPVPLTPWVFGVTAGVFLYVALVDMLPALLRPPEPLPTPHVLLQGLGLLLGGGLMLAITLLEERLLPVTTEG |
| 分子量 | 82.83 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SLC39A5蛋白研究的示例参考文献(注：以下内容为模拟示例，实际文献需通过学术数据库验证)：
1. **"Functional characterization of recombinant human SLC39A5 (ZIP5) as a zinc transporter"**
*作者：Wang F. et al.*
**摘要**：通过哺乳动物细胞表达重组SLC39A5蛋白，证实其定位于细胞质膜，并参与细胞内锌离子的摄取调控，提示其在维持锌稳态中的关键作用。
2. **"SLC39A5 regulates intestinal zinc absorption via recombinant protein-mediated transport studies"**
*作者：Kimura T. et al.*
**摘要**：利用重组SLC39A5蛋白模型，揭示其在肠道上皮细胞中特异性表达，并通过锌离子跨膜转运影响体内锌吸收的分子机制。
3. **"Crystal structure and metal-binding properties of the recombinant human ZIP5 (SLC39A5) ectodomain"**
*作者：Zhang Y. et al.*
**摘要**：解析重组SLC39A5胞外域晶体结构，阐明其锌离子结合位点，为设计靶向该蛋白的代谢疾病疗法提供结构基础。
4. **"SLC39A5 overexpression in hepatocellular carcinoma: Implications for zinc dysregulation"**
*作者：Li M. et al.*
**摘要**：通过重组SLC39A5在肝癌细胞中的过表达实验，发现其异常表达导致细胞内锌失衡，促进肿瘤生长和转移。
**建议**：实际研究中可查阅PubMed或Google Scholar，结合关键词“SLC39A5 recombinant”“ZIP5 zinc transport”获取最新文献。
The human SLC39A5 protein, also known as ZIP5. belongs to the ZRT-/IRT-like protein (ZIP) family, a group of zinc transporters critical for maintaining cellular zinc homeostasis. It facilitates zinc uptake from extracellular environments or intracellular compartments into the cytoplasm, playing a pivotal role in zinc metabolism. Structurally, SLC39A5 contains eight transmembrane domains and is typically localized to the plasma membrane, particularly in tissues involved in zinc absorption or secretion, such as the intestine, liver, and pancreas. Dysregulation of SLC39A5 has been implicated in pathologies including cancer progression, metabolic disorders, and immune dysfunction, as zinc signaling influences processes like cell proliferation, apoptosis, and antioxidant defense.
Recombinant human SLC39A5 is produced via genetic engineering in systems like mammalian cells or bacteria, enabling studies of its biochemical properties, substrate specificity, and interaction partners. Researchers utilize purified recombinant SLC39A5 to investigate zinc transport mechanisms, map its tissue-specific roles, and explore links to diseases like diabetes or neurodegenerative conditions. Additionally, it serves as a tool for screening potential therapeutic agents targeting zinc-related pathways. Its therapeutic potential lies in modulating zinc levels to correct deficiencies or mitigate toxicity, though clinical applications require further validation. Current research also focuses on its epigenetic regulation and impact on inflammatory responses, highlighting its multifaceted role in human health.
×
